Pharmaceutical

Risk adjusted net present value: What is the current valuation of Spur Therapeutics’s FLT-201?

FLT-201 is a gene therapy commercialized by Spur Therapeutics, with a leading Phase II program in Gaucher Disease Type I.

Jul 2, 2024 - 04:00
FLT-201 is a gene therapy commercialized by Spur Therapeutics, with a leading Phase II program in Gaucher Disease Type I.
Read the original article

Tags:

Previous Article

Flatiron Institute launches initiative for computational catalysis

Next Article

Risk adjusted net present value: What is the current valuation of Pfizer’s PF-07...

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

Vertex licenses Editas’ gene editing technology in $100m deal

Vertex licenses Editas’ gene editing technology in $100...

Dec 14, 2023

Nuntius partners with Taiho to develop mRNA cancer therapies

Nuntius partners with Taiho to develop mRNA cancer ther...

Aug 17, 2024

STAT+: Revenue cycle management company Waystar files for IPO

STAT+: Revenue cycle management company Waystar files f...

Oct 18, 2023